Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 88 (high attention) · dilution pressure elevated · listing risk high · governance risk low · runway 23.2 mo · strongest signal: MVLS deficiency (Sep 2, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 16, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-09-16 filing | 39 |
| Sep 2, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (8-K) filed 2026-09-02 filing | 51 |
| Sep 2, 2026 | ▼ Equity deficiency | “stockholders equity deficiency” language in 8-K (8-K) filed 2026-09-02 filing | 42 |
| Sep 2, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-09-02 filing | 39 |
| Sep 2, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-09-02 filing | 35 |
| Aug 27, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-08-27 filing | 40 |
| Aug 24, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-24 filing | 24 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 15,798,031 (2026-05-07) -> 34,141,460 (2026-08-05), +116% filing | 40 |
DAIC CID Holdco, Inc. · SDST Stardust Power Inc. · ISPC iSpecimen Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · BRTX BioRestorative Therapies, In · screener →